Burke Steven Keith 4
4 · Akebia Therapeutics, Inc. · Filed Feb 2, 2024
Insider Transaction Report
Form 4
Burke Steven Keith
SVP, Chief Medical Officer
Transactions
- Award
Common Stock
2024-01-31+202,200→ 735,687 total - Award
Stock Option (Right to buy)
2024-01-31+303,300→ 303,300 totalExercise: $1.68Exp: 2034-01-31→ Common Stock (303,300 underlying) - Sale
Common Stock
2024-02-01$1.68/sh−24,311$40,842→ 711,376 total
Footnotes (4)
- [F1]The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
- [F2]Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
- [F3]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31,2023.
- [F4]The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.